IDO1 and neoplasm: IDO, an intracellular enzyme in MDSCs mediating tryptophan metabolism, hinders CAR-T therapy efficacy via tryptophan metabolites, and a tumor model showed that IDO inhibitor could restore the therapeutic effect (Fan et al., 2017).